1. Ibrutinib in Previously Treated Waldenström's Macroglobulinemia.
- Author
-
Treon, Steven P., Tripsas, Christina K., Meid, Kirsten, Warren, Diane, Varma, Gaurav, Green, Rebecca, Argyropoulos, Kimon V., Guang Yang, Yang Cao, Lian Xu, Patterson, Christopher J., Rodig, Scott, Zehnder, James L., Aster, Jon C., Harris, Nancy Lee, Kanan, Sandra, Ghobrial, Irene, Castillo, Jorge J., Laubach, Jacob P., and Hunter, Zachary R.
- Subjects
- *
WALDENSTROM'S macroglobulinemia , *MEDICAL centers , *LYMPHOCYTOSIS , *NEUTROPENIA , *THROMBOCYTOPENIA , *ATRIAL fibrillation , *THERAPEUTICS - Abstract
The article discusses a study on the drug ibrutinib in previously treated patients with Waldenström's macroglobulinemia at various medical centers in the U.S., and examines the effect of MYD88 and CXCR4 mutations on outcomes. Topics mentioned include the effect of ibrutinib on peripheral lymphocytosis, adverse events linked to ibrutinib therapy, such as neutropenia, thrombocytopenia, and atrial fibrillation, and the effect of ibrutinib therapy on extramedullary disease.
- Published
- 2015
- Full Text
- View/download PDF